ALX cuts two an­ti-CD47 pro­grams just weeks af­ter Gilead stopped a piv­otal study of its own can­di­date

ALX On­col­o­gy is cut­ting two stud­ies of its an­ti-CD47 drug evor­pacept af­ter it failed to show sub­stan­tial ef­fi­ca­cy.

In its sec­ond-quar­ter re­port Thurs­day af­ter­noon, ALX …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER